@article{51a2302e9e944fefada7721074337c7b,
title = "ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma",
author = "Akihiko Okamura and Satoru Matsuda and Hirofumi Kawakubo and Shinji Mine and Hiroya Takeuchi and Yuko Kitagawa and Masayuki Watanabe",
note = "Funding Information: None declared conflicts of interests for this study. Conflicts of interests outside this work are as follows; Yuko Kitagawa received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Merck Serono, Asahi Kasei, EA Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical Factory, Shionogi, Kaken Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Medicon, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Kyouwa Hakkou Kirin, Pfizer Japan, Ono Pharmaceutical, Nihon Pharmaceutical, Japan Blood Products Organization, Medtronic Japan, Sanofi K.K. grants from Eisai, Tsumura, KCI Licensing, Abbott Japan, and Fujifilm Toyama Chemical. ",
year = "2020",
month = dec,
doi = "10.1245/s10434-020-08772-4",
language = "English",
volume = "27",
pages = "795--796",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
}